Intellia Therapeutics price target raised to $20 from $19 at BofA

BofA analyst Alec Stranahan raised the firm’s price target on Intellia Therapeutics (NTLA) to $20 from $19 and keeps a Neutral rating on the shares. Phase 3 HAELO data support the HAE thesis but don’t fully resolve debates around Intellia, as efficacy appears comparable and not clearly superior to competitors, the analyst tells investors in a research note. While regulatory momentum looks positive with a planned BLA filing and potential 2027 launch, the key question is whether physicians will require more durability data before switching stable patients to a one-time gene-editing treatment, the firm says.